Clinical Trial Update: Safety Evaluation of 3K3A-APC in Ischemic Stroke [Phase 2]

View source ↗

Summary

Phase 2 safety evaluation update for 3K3A-APC in ischemic stroke has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• 3K3A-APC (3K3A-activated protein C)

Snippet

Sponsor: ZZ Biotech, LLC | Conditions: Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2018-11-08